69
Participants
Start Date
October 1, 2018
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2026
Stereotactic Body Radiotherapy
(27 Gy over 3 fractions)
Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder)
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Westchester, Harrison
Memorial Sloan Kettering Nassau, Uniondale
Memorial Sloan Kettering Rockville Centre, Rockville Centre
Memorial Sloan Kettering Commack, Commack
Lehigh Valley Health Network, Allentown
Hartford Healthcare, Hartford
Memorial Sloan Kettering Basking Ridge, Basking Ridge
Memorial Sloan Kettering Monmouth, Middletown
Memorial Sloan Kettering Bergen, Montvale
Memorial Sloan Kettering Cancer Center
OTHER